{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:14:34Z","timestamp":1787170474033,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.autrev.2023.103438","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:57:44Z","timestamp":1693342664000},"page":"103438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis?"],"prefix":"10.1016","volume":"23","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eithne","family":"Nic An R\u00edogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.autrev.2023.103438_bb0005","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/rheumatology\/kez148","article-title":"Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum","volume":"58","author":"Mahr","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103438_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0025","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/art.34590","article-title":"How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al.","volume":"64","author":"Sch\u00f6nermarck","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0035","first-page":"153","article-title":"Updates in ANCA-associated vasculitis","volume":"9","author":"Ross","year":"2022","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.autrev.2023.103438_bb0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103438_bb0045","first-page":"3","article-title":"Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis","author":"Heijl","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103438_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez618","article-title":"Complications of therapy for ANCA-associated vasculitis","volume":"59","author":"Smith","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103438_bb0055","first-page":"1","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"0","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0060","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ekir.2022.02.020","article-title":"A meta-analysis of the safety and efficacy of maintenance therapies for antineutrophil cytoplasmic antibody small-vessel vasculitis","volume":"7","author":"Bellos","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2023.103438_bb0065","first-page":"188","article-title":"Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study","volume":"38","author":"Padoan","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103438_bb0070","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.lpm.2015.02.019","article-title":"Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis","volume":"44","author":"Flossmann","year":"2015","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0080","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0085","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0090","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2023.103438_bb0095","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Trejo","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103438_bb0105","first-page":"201","article-title":"Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"38","author":"Felicetti","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103438_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0120","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ekir.2019.01.004","article-title":"Understanding long-term remission off therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Hogan","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2023.103438_bb0130","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/ar4066","article-title":"Th17 expansion in granulomatosis with polyangiitis (Wegener\u2019s): the role of disease activity, immune regulation and therapy","volume":"14","author":"Wilde","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103438_bb0140","doi-asserted-by":"crossref","first-page":"8209737","DOI":"10.1155\/2020\/8209737","article-title":"Increased frequencies of switched memory B cells and plasmablasts in peripheral blood from patients with ANCA-associated vasculitis","volume":"2020","author":"Elm\u00e9r","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2023.103438_bb0145","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/annrheumdis-2012-202986","article-title":"Regulatory B cells in ANCA-associated vasculitis","volume":"72","author":"Wilde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0150","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/art.22692","article-title":"Functional defect of circulating regulatory CD4+ T cells in patients with Wegener\u2019s granulomatosis in remission","volume":"56","author":"Abdulahad","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2023.103438_bb0160","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/ndt\/gfu042","article-title":"Repeat protocol renal biopsy in ANCA-associated renal vasculitis","volume":"29","author":"Hruskova","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2023.103438_bb0165","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.39620","article-title":"HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study","volume":"68","author":"Hilhorst","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2023.103438_bb0170","first-page":"8","article-title":"PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease","author":"Chen","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2023.103438_bb0175","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2023.103438_bb0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard-2022-222479","article-title":"Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission","volume":"82","author":"Gamerith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0195","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103438_bb0200","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103438_bb0205","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103438_bb0210","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2023.103438_bb0215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2023.103438_bb0220","article-title":"Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement","volume":"26","author":"Roccatello","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103438_bb0225","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy","volume":"26","author":"Roccatello","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2023.103438_bb0230","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103438_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10020292","article-title":"A 3-year observational study of patients with progressive systemic sclerosis treated with an intensified B lymphocyte depletion protocol: clinical and immunological response","volume":"10","author":"Rossi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0240","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ekir.2021.01.027","article-title":"A prospective study on long-term clinical outcomes of patients with lupus nephritis treated with an intensified B-cell depletion protocol without maintenance therapy","volume":"6","author":"Roccatello","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2023.103438_bb0245","first-page":"13","article-title":"Treating patients with ANCA-associated vasculitis and very severe renal injury with an intensified B cell depletion therapy: comparison with a control cohort receiving a conventional therapy","author":"Roccatello","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103438_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803175","article-title":"A personalized rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis","volume":"12","author":"Arnold","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103438_bb0255","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103438_bb0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103438_bb0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement","volume":"18","author":"Moura","year":"2023","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T19:49:30Z","timestamp":1712519370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1568997223001726"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103438","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103438"}}